IS8111A - Kristallað form af beta-2 adrenvirku viðtaka gerandefni - Google Patents
Kristallað form af beta-2 adrenvirku viðtaka gerandefniInfo
- Publication number
- IS8111A IS8111A IS8111A IS8111A IS8111A IS 8111 A IS8111 A IS 8111A IS 8111 A IS8111 A IS 8111A IS 8111 A IS8111 A IS 8111A IS 8111 A IS8111 A IS 8111A
- Authority
- IS
- Iceland
- Prior art keywords
- beta
- crystalline form
- receptor agonist
- adrenergic receptor
- adrenergic
- Prior art date
Links
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 title 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 title 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47342303P | 2003-05-27 | 2003-05-27 | |
| PCT/US2004/016602 WO2004106279A2 (en) | 2003-05-27 | 2004-05-26 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8111A true IS8111A (is) | 2005-10-31 |
Family
ID=33490599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8111A IS8111A (is) | 2003-05-27 | 2005-10-31 | Kristallað form af beta-2 adrenvirku viðtaka gerandefni |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7557247B2 (is) |
| EP (1) | EP1641744A2 (is) |
| JP (1) | JP2007500233A (is) |
| KR (1) | KR20060017616A (is) |
| CN (1) | CN100528835C (is) |
| AR (1) | AR045317A1 (is) |
| AU (1) | AU2004243304A1 (is) |
| BR (1) | BRPI0410705A (is) |
| CA (1) | CA2525839A1 (is) |
| CO (1) | CO5650226A2 (is) |
| IS (1) | IS8111A (is) |
| MA (1) | MA27779A1 (is) |
| MX (1) | MXPA05012678A (is) |
| NO (1) | NO20056132L (is) |
| NZ (1) | NZ543355A (is) |
| RU (1) | RU2005140652A (is) |
| TW (1) | TW200510277A (is) |
| WO (1) | WO2004106279A2 (is) |
| ZA (1) | ZA200510104B (is) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| CA2561400A1 (en) * | 2004-04-02 | 2005-10-13 | Glaxo Group Limited | Chemical process and new crystalline form |
| WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| US8420286B2 (en) * | 2008-03-27 | 2013-04-16 | Xerox Corporation | Toner process |
| US8367294B2 (en) * | 2008-03-27 | 2013-02-05 | Xerox Corporation | Toner process |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US676793A (en) * | 1899-09-12 | 1901-06-18 | A D Fenwick Machine Co | Pasting-machine for collars, &c. |
| US654117A (en) * | 1899-11-29 | 1900-07-17 | Henry B Maddocks | Coal-bucket. |
| US4064125A (en) * | 1976-10-29 | 1977-12-20 | E. R. Squibb And Sons, Inc. | Substituted amides having antiinflammatory activity |
| IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| HU196775B (en) * | 1986-08-05 | 1989-01-30 | Richter Gedeon Vegyeszet | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
| US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
| US5872126A (en) | 1996-09-06 | 1999-02-16 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
| GB9713819D0 (en) * | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
| SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
| US6350738B1 (en) * | 1998-03-06 | 2002-02-26 | Brigham Young University | Steroid derived antibiotics |
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6683115B2 (en) * | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| KR20090057477A (ko) | 2001-09-14 | 2009-06-05 | 글락소 그룹 리미티드 | 호흡기 질환 치료용 펜에탄올아민 유도체 |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| JP2005523920A (ja) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | フェネタノールアミン誘導体 |
| AR040661A1 (es) | 2002-07-26 | 2005-04-13 | Theravance Inc | Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2 |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| US8501994B2 (en) * | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
-
2004
- 2004-05-17 TW TW093113868A patent/TW200510277A/zh unknown
- 2004-05-24 AR ARP040101794A patent/AR045317A1/es unknown
- 2004-05-26 WO PCT/US2004/016602 patent/WO2004106279A2/en not_active Ceased
- 2004-05-26 RU RU2005140652/04A patent/RU2005140652A/ru not_active Application Discontinuation
- 2004-05-26 AU AU2004243304A patent/AU2004243304A1/en not_active Abandoned
- 2004-05-26 EP EP04753431A patent/EP1641744A2/en not_active Ceased
- 2004-05-26 BR BRPI0410705-5A patent/BRPI0410705A/pt not_active IP Right Cessation
- 2004-05-26 KR KR1020057022542A patent/KR20060017616A/ko not_active Ceased
- 2004-05-26 CA CA002525839A patent/CA2525839A1/en not_active Abandoned
- 2004-05-26 CN CNB200480014438XA patent/CN100528835C/zh not_active Expired - Fee Related
- 2004-05-26 US US10/854,405 patent/US7557247B2/en not_active Expired - Lifetime
- 2004-05-26 JP JP2006533430A patent/JP2007500233A/ja active Pending
- 2004-05-26 NZ NZ543355A patent/NZ543355A/en unknown
- 2004-05-26 MX MXPA05012678A patent/MXPA05012678A/es unknown
-
2005
- 2005-10-31 IS IS8111A patent/IS8111A/is unknown
- 2005-11-21 MA MA28612A patent/MA27779A1/fr unknown
- 2005-12-12 ZA ZA200510104A patent/ZA200510104B/xx unknown
- 2005-12-22 CO CO05129154A patent/CO5650226A2/es not_active Application Discontinuation
- 2005-12-22 NO NO20056132A patent/NO20056132L/no not_active Application Discontinuation
-
2007
- 2007-01-16 US US11/654,117 patent/US20070155990A1/en not_active Abandoned
-
2009
- 2009-05-13 US US12/465,350 patent/US7772434B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AR045317A1 (es) | 2005-10-26 |
| US7772434B2 (en) | 2010-08-10 |
| MXPA05012678A (es) | 2006-02-22 |
| NO20056132L (no) | 2006-01-26 |
| AU2004243304A1 (en) | 2004-12-09 |
| WO2004106279A2 (en) | 2004-12-09 |
| US20040248985A1 (en) | 2004-12-09 |
| RU2005140652A (ru) | 2006-04-20 |
| CA2525839A1 (en) | 2004-12-09 |
| WO2004106279A3 (en) | 2005-02-03 |
| NZ543355A (en) | 2009-06-26 |
| MA27779A1 (fr) | 2006-02-01 |
| EP1641744A2 (en) | 2006-04-05 |
| US7557247B2 (en) | 2009-07-07 |
| JP2007500233A (ja) | 2007-01-11 |
| CO5650226A2 (es) | 2006-06-30 |
| TW200510277A (en) | 2005-03-16 |
| BRPI0410705A (pt) | 2006-06-13 |
| CN1795169A (zh) | 2006-06-28 |
| US20070155990A1 (en) | 2007-07-05 |
| CN100528835C (zh) | 2009-08-19 |
| US20100125150A1 (en) | 2010-05-20 |
| KR20060017616A (ko) | 2006-02-24 |
| ZA200510104B (en) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8111A (is) | Kristallað form af beta-2 adrenvirku viðtaka gerandefni | |
| DE60232171D1 (de) | Arylanilin beta-2 adrenergische rezeptor agoniste | |
| DK1664036T3 (da) | Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning | |
| MA28902B1 (fr) | Agonistes des recepteurs beta2 adrenergiques diaminiques | |
| DK1562595T3 (da) | Diarylethere som opioidreceptorantagonister | |
| DE602005011132D1 (de) | Neuartige cis-imidazoline | |
| DE602004030930D1 (de) | Muscarinische acetylcholin-rezeptor-antagonisten | |
| DK2959774T3 (da) | Fremgangsmåde til kryokonservering af sædceller | |
| IS7505A (is) | Pýrróló-tríazín anilín efnasambönd gagnleg sem kínasatálmar | |
| DK1973559T3 (da) | Activin-ActRIIa antagonister samt anvendelser til fremme af knoglevækst | |
| DK1854454T3 (da) | Fremgangsmåde til fremstilling af amorf telmisartan | |
| IS2790B (is) | Mótefni gegn viðtaka insúlínlíks vaxtarþáttar af gerð I | |
| DK1992697T3 (da) | Fremstilling af TNFR-Fc | |
| DK1615889T3 (da) | Biphenylderivater med beta2-adrenergisk receptoragonist- og muscarinisk receptorantagonistaktivitet | |
| DE60330392D1 (de) | Cb 1 rezeptor inversagonisten | |
| DE602005022986D1 (de) | Kristalline polymorphe eines cxc-chemokinrezeptorliganden | |
| DK1687257T3 (da) | Aminosubstituerede ethylaminoagonister af den beta2-adrenerge receptor | |
| NO20054868D0 (no) | CaSr antagonist | |
| DK1711465T3 (da) | Hydroisoindolin-tachykinikreceptorantagonister | |
| DK1487840T3 (da) | Krystallinsk polymorf form af irinotecan hydrochlorid | |
| DK2336124T3 (da) | Stabilt hydrat af en muscarinreceptorantagonist | |
| DK1940465T3 (da) | Ny anvendelse af anti-IL-1beta-antistoffer | |
| DK1597232T3 (da) | Ny krystallinsk modifikation af anhydratet af boscalid | |
| DK1973886T3 (da) | Prokineticin-1-receptor-antagonister | |
| MA28364A1 (fr) | Formes polymorphes d'un agoniste gabaa |